Who
Lewis T. Williams
Director
Company insider
Files Form 4 as: Director, Protagonist Therapeutics; Director, Arcellx; Director, Neurogene; Executive Chairman, Five Prime Therapeutics; Director, Beckman Coulter.
In numbers
- Trades disclosed
- 152
- Buys
- 0
- Sells
- 21
- Bought
- $0
- Sold
- $18.0M
- Companies
- 5
- Companies where not an officer
- 4
- First trade
- 2 Nov 2009
- Last trade
- 17 Feb 2026
- Last filed
- 18 Feb 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 17 Feb 2026filed 18 Feb 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $195K18,000 at $10.84 | filing |
| 17 Feb 2026filed 18 Feb 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.5M18,000 at $82.42 | filing |
| 17 Feb 2026filed 18 Feb 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,000 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —18,000 at $0.00 | filing |
| 17 Feb 2026filed 18 Feb 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code M | $195K18,000 at $10.84 | filing |
| 17 Feb 2026filed 18 Feb 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Sold | $1.5M18,000 at $82.42 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,695 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,762 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,762 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code A | —2,695 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —6,584 at $0.00 | filing |
| 2 Jan 2025filed 6 Jan 2025 | PTGX Protagonist TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,130 at $0.00 | filing |
| 2 Jan 2024filed 4 Jan 2024 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,700 at $0.00 | filing |
| 16 Jan 2023filed 18 Jan 2023 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —30,000 at $0.00 | filing |
| 26 May 2022filed 27 May 2022 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —20,000 at $0.00 | filing |
| 8 Feb 2022filed 9 Feb 2022 | Arcellxoption or derivative | SEC FORM 4 Code C | —1,163,886 at $0.00 | filing |
| 8 Feb 2022filed 9 Feb 2022 | Arcellxoption or derivative | SEC FORM 4 Code C | —931,228 at $0.00 | filing |
| 8 Feb 2022filed 9 Feb 2022 | Arcellx | SEC FORM 4 Code C | —2,095,114 at $0.00 | filing |
| 27 May 2021filed 28 May 2021 | PTGX Protagonist Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,000 at $0.00 | filing |
| 11 May 2021filed 13 May 2021 | NGNE Neurogeneoption or derivative · Biotechnology | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
News
Comparing Sarepta Therapeutics (NASDAQ:SRPT) and Protagonist Therapeutics (NASDAQ:PTGX)PTGX · dailypolitical.com · 22 Oct 2026Protagonist Therapeutics (NASDAQ:PTGX) Downgraded by Wall Street Zen to BuyPTGX · dailypolitical.com · 11 Oct 2026
0 headlines in the last 90 days name Lewis T. Williams; 2 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.